Cipla Limited (BOM:500087)
India · Delayed Price · Currency is INR 1,359.75
-1.25 (-0.09%)
At close: Sep 16, 2026
Cipla Revenue
Cipla had revenue of 70.77B INR in the quarter ending June 30, 2026, with 3.51% growth. This brings the company's revenue in the last twelve months to 280.68B, up 2.14% year-over-year. In the fiscal year ending March 31, 2026, Cipla had annual revenue of 278.28B with 2.06% growth.
Revenue (ttm)
280.68B
Revenue Growth
+2.14%
P/S Ratio
3.89
Revenue / Employee
8.95M
Employees
31,369
Market Cap
1.09T
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 278.28B | 5.60B | 2.06% |
| Mar 31, 2025 | 272.67B | 17.31B | 6.78% |
| Mar 31, 2024 | 255.37B | 29.77B | 13.20% |
| Mar 31, 2023 | 225.59B | 8.51B | 3.92% |
| Mar 31, 2022 | 217.08B | 25.87B | 13.53% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Dr. Reddy's Laboratories | 331.19B |
| Lupin | 299.67B |
| Torrent Pharmaceuticals | 157.23B |
| Jubilant Pharmova | 86.08B |
| Abbott India | 70.04B |
| Granules India | 56.32B |
| J. B. Chemicals & Pharmaceuticals | 41.48B |
| GlaxoSmithKline Pharmaceuticals | 39.55B |
Cipla News
- 13 days ago - India's Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar - Reuters
- 17 days ago - ‘You’re going overboard’: Bombay high court to FDA, restores Cipla’s licence - The Times of India
- 18 days ago - After Bombay HC rap, FDA withdraws orders against Cipla, MCA eateries - The Times of India
- 18 days ago - Maharashtra FDA cancels Cipla unit’s drug sale licences in Pune - The Times of India
- 18 days ago - Maharashtra FDA cancels Pune Cipla facility’s sale licences over ‘lapses’ - The Times of India
- 19 days ago - Misbranding, storage lapses: FDA cancels Cipla Pune unit’s drug licence over Reactin Plus violations - The Times of India
- 6 weeks ago - Weekly Buzz:CIPLA, VTRS Win FDA Nod; BSX Cuts Jobs; ARGX Snaps Up FBRX; JNJ, GSK Strike Deals - Nasdaq
- 7 weeks ago - Cipla Receives FDA Approval For Generic Advair Diskus In All Strengths - Nasdaq